KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding
Others
Ratios

AbCellera Biologics (ABCL) EBITDA (2020 - 2023)

Historic EBITDA for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to -$47.4 million.

  • AbCellera Biologics' EBITDA fell 5510.19% to -$47.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$146.7 million, marking a year-over-year decrease of 19354.73%. This contributed to the annual value of -$165.5 million for FY2024, which is 1280.47% down from last year.
  • Per AbCellera Biologics' latest filing, its EBITDA stood at -$47.4 million for Q4 2023, which was down 5510.19% from -$28.2 million recorded in Q3 2023.
  • AbCellera Biologics' 5-year EBITDA high stood at $169.1 million for Q1 2022, and its period low was -$47.4 million during Q4 2023.
  • Over the past 4 years, AbCellera Biologics' median EBITDA value was -$2.4 million (recorded in 2020), while the average stood at $17.7 million.
  • In the last 5 years, AbCellera Biologics' EBITDA skyrocketed by 562408.11% in 2021 and then plummeted by 399122.81% in 2022.
  • AbCellera Biologics' EBITDA (Quarter) stood at $117.0 million in 2020, then crashed by 49.07% to $59.6 million in 2021, then crashed by 151.3% to -$30.6 million in 2022, then tumbled by 55.1% to -$47.4 million in 2023.
  • Its last three reported values are -$47.4 million in Q4 2023, -$28.2 million for Q3 2023, and -$30.4 million during Q2 2023.